SARS-COV-2 IgG antibody response in pregnant women at delivery - 10/12/20

Doi : 10.1016/j.jogoh.2020.102041

Vassilis Tsatsaris ^a,^b,⁎ , Alice-Andrée Mariaggi ^a,^c,^{^{1
Both authors contributed equally to the work.}}, Odile Launay ^a,^d,^{^{1
Both authors contributed equally to the work.}}, Camille Couffignal ^a,^e, Jessica Rousseau ^f, Pierre Yves Ancel ^a,^f, Estelle Marcault ^a,^e, Yves Ville ^a,^g, Anne-Gaël Cordier ^h, Alexandre Vivanti ^i,^j, Julie Carrara ^j, Dominique Luton ^a,^k,^s, Marc Dommergues ^l,^m, Constance Borie ^a,ⁿ, Gilles Kayem ^l,^o, Vivien Alessandrini ^a,^b, Laurence Lecomte ^f, Jean François Meritet ^b, Marianne Leruez-Ville ^p, François Goffinet ^a,^b, Claire Dubois ^a,^q, Olivier Picone ^a,^r, Christelle Vauloup Fellous ^i,^q
The COVIPREG study group
H. Abdoul, V. Alessandrini, P.Y. Ancel, E. Azria, A. Benachi, C. Borie, V. Buth, C. Cabanne, J. Carrara, A.G. Cordier, C. Couffignal, M. Dommergues, S. Dreux, C. Dubois, E. Dufour, M. Eloit, J. Guibourdenche, O. Launay, L. Lecomte, F. Goffinet, C. Guettouche, G. Kayem, M. Leruez-Ville, D. Luton, L. Mandelbrot, E. Marcault, A.A. Mariaggi, J.F. Meritet, B. Parfait, P. Peretout, O. Picone, S. Prieur, J. Rousseau, F. Rozenberg, J. Sibiude, V. Tsatsaris, Ch. Vauloup Fellous, A. Vivanti, Y. Ville

^a Université de Paris, F-75006 Paris, France
^b Maternité Port-Royal, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
^c Laboratoire de Virologie, AP-HP, Hôpital Cochin, F-75014 Paris, France
^d CIC vaccinologie, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
^e Unité de recherche clinique PNVS, AP-HP, Hôpital Bichat, F-75018 Paris, France
^f Unité de recherche clinique, CIC-Mère enfant, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
^g Maternité, AP-HP, Hôpital Necker, F-75007 Paris, France
^h Maternité, AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
ⁱ Université Paris-Saclay, 94804 Villejuif, France
^j Maternité, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, France
^k Maternité, AP-HP, Hôpital Bichat, F-75018 Paris, France
^l Sorbonne Université, F-75006 Paris, France
^m Maternité, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
ⁿ Maternité, AP-HP, Hôpital Robert Debré, F-75019 Paris, France
^o Maternité, AP-HP, Hôpital Trousseau, F-75012 Paris, France
^p Laboratoire de Virologie, AP-HP, Hôpital Necker, F-75007 Paris, France
^q Laboratoire de Virologie, AP-HP, Hôpital Paul-Brousse, F-94804 Villejuif, France
^r Maternité, AP-HP, Hôpital Louis Mourier, F-75007 Paris, France
^s Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France

^⁎Corresponding author at: Hôpital Cochin, Maternité Port-Royal, AP-HP, FHU PREMA, Université de Paris, 123 Bd Port-Royal F-75014 Paris, France.Hôpital CochinMaternité Port-RoyalAP-HP, FHU PREMAUniversité de Paris123 Bd Port-RoyalParisF-75014France

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Thursday 10 December 2020
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Background

The prevalence of COVID-19 infection during pregnancy is not known. COVIPREG is a prospective French multicenter study to assess the seroprevalence at the time of delivery and the maternal and neonatal impact of COVID-19 infection during pregnancy. In order to study factors associated with poor outcomes after COVID-19 Infection during pregnancy and adapt the sample size of the study, a preliminary assessment of the prevalence of SARS-CoV-2 IgG was planned after 500 inclusions in a one perinatal center of Paris area.

Objectives

To assess the prevalence of SARS-CoV-2 IgG antibody response in pregnant women at the time of delivery during the COVID-19 pandemia.

Study design

A prospective observational study at Cochin hospital (Level III maternity). Patients admitted for delivery were offered to participate to the study. Each patient participating to the study was tested for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA.

Results

Among the 529 patients included in the COVIPREG study between April 29 and June 26, 529 were assessed for SARS-CoV-2 IgG antibody response and 25 had a positive test, ie 4.7% with a confidence interval at 95% [3.0%-6.9%]).

Conclusions

Four months after the beginning of the infection in Paris, the seroprevalence of SARS-CoV-2 IgG in pregnant women at the time of delivery is low. Studies evaluating the impact of COVID-19 infection during pregnancy should take this information in account in order to adapt the sample size.

Le texte complet de cet article est disponible en PDF.

Keywords : Pregnancy, COVID-19, SARS-CoV-2, seroprevalence